Globe Newswire05.24.16
MEDTECH, a company that designs, develops and markets surgical assistance robots, announced the first surgical operation with the ROSA Spine in Spain. The procedure, which was performed at Hospital La Fe of Valencia, treated a patient with degenerative disc disease.
Degenerative disc disease is a condition in which pain is caused from a damaged spinal disc, most often as a result of aging. The operation, which consists of fusing lumbar vertebrae to reduce back pain, was performed on a 47-year-old patient by Dr. Carlos Botella, a neurosurgeon at La Fe Hospital of Valencia. La Fe is a University-based Hospital that is recognized as a leading European facility for the treatment of brain and spine pathologies.
“ROSA Spine allows us to perform minimally invasive surgical interventions that track and adjust for the patient’s body movements during the procedure. As a result, we have increased confidence that the instrument and implant positioning is aligned with the planned trajectory, facilitating a highly accurate outcome,” said Botella, a neurosurgeon specializing in the treatment of neurological and spinal disorders.
“There is increasing interest in robotically assisted, minimally-invasive spine surgery and we are pleased with the continued expansion of our ROSA Spine system in the marketplace,” said Bertin Nahum, CEO and founder of Medtech. “Patients in Spain now have access to our robotic technology for spine surgery and I would like to thank La Fe Hospital for contributing to the advancement of minimally invasive techniques. This procedure also highlights the growing adoption of our robotic technology for neurological and spinal procedures by surgical teams throughout Europe.”
Founded in 2002 by Nahum and based in Montpellier, France, MEDTECH’s robotic devices help surgeons during their procedures. The company developed ROSA, a device devoted to brain surgery procedures, nine years ago. ROSA has been approved in Europe, the United States and Canada.
MEDTECH obtained CE mark approval in July 2014 for ROSA Spine, a robotic-assistive device for minimally invasive surgery of the spine. In January (2016), the U.S. Food and Drug Administration cleared ROSA Spine for use in the United States.
Degenerative disc disease is a condition in which pain is caused from a damaged spinal disc, most often as a result of aging. The operation, which consists of fusing lumbar vertebrae to reduce back pain, was performed on a 47-year-old patient by Dr. Carlos Botella, a neurosurgeon at La Fe Hospital of Valencia. La Fe is a University-based Hospital that is recognized as a leading European facility for the treatment of brain and spine pathologies.
“ROSA Spine allows us to perform minimally invasive surgical interventions that track and adjust for the patient’s body movements during the procedure. As a result, we have increased confidence that the instrument and implant positioning is aligned with the planned trajectory, facilitating a highly accurate outcome,” said Botella, a neurosurgeon specializing in the treatment of neurological and spinal disorders.
“There is increasing interest in robotically assisted, minimally-invasive spine surgery and we are pleased with the continued expansion of our ROSA Spine system in the marketplace,” said Bertin Nahum, CEO and founder of Medtech. “Patients in Spain now have access to our robotic technology for spine surgery and I would like to thank La Fe Hospital for contributing to the advancement of minimally invasive techniques. This procedure also highlights the growing adoption of our robotic technology for neurological and spinal procedures by surgical teams throughout Europe.”
Founded in 2002 by Nahum and based in Montpellier, France, MEDTECH’s robotic devices help surgeons during their procedures. The company developed ROSA, a device devoted to brain surgery procedures, nine years ago. ROSA has been approved in Europe, the United States and Canada.
MEDTECH obtained CE mark approval in July 2014 for ROSA Spine, a robotic-assistive device for minimally invasive surgery of the spine. In January (2016), the U.S. Food and Drug Administration cleared ROSA Spine for use in the United States.